FCGR3A and thyroid cancer: Finally, engineering NK cells to express high-affinity CD16 variants (FcγRIIIa) has shown promise in boosting antibody-dependent cellular cytotoxicity (ADCC) when combined with monoclonal antibodies targeting EGFR or VEGF, both of which are upregulated in thyroid cancer [37].